All five commissioners agreed, cyber threats are the number one threat to the grid.
Edward Markey
The Public Record
Edward John Markey is a United States Senator from Massachusetts, having served since July 24, 2013. A member of the Democratic Party, Markey previously represented Massachusetts in the U.S. House of Representatives from April 14, 1976, to July 24, 2013. Throughout his career, he has been a strong advocate for environmental issues, telecommunications, and technology policy. Markey played a significant role in the development of legislation aimed at addressing climate change and promoting renewable energy sources.
It is imperative that this committee pass the GRID Act so that we can move it forward and empower the FERC to move quickly to safeguard the electric grid from cyber threats.
Last week, FBI Director Robert Mueller testified that cyber threats will soon surpass terrorism as the number one threat facing the United States.
It is Groundhog Day here in the House with the same hearings, the same bills, the same votes over and over again.
Mr. Speaker, on that I demand the yeas and nays. The yeas and nays were ordered. The SPEAKER pro tempore. Pursuant to clause 8 and clause 9 of rule XX, this 15-minute vote on the motion to recommit will be followed by 5-minute votes on…
So this is something that Ms. Eshoo and I are working on, this next subject, which is that the FDA data shows that since 2007, 78 percent of PREA's pediatric study requirements were not completed by their due dates, if at all.
the academy also wishes to acknowledge and thank Representatives Mike Rogers and Ed Markey, who together authored the Pediatric Medical Device Safety and Improvement Act of 2007.
So if you would be willing to work with us, we are willing to work with you and with Mr. Pallone and others to see if we can do something legislatively in this area.
The Web site clinicaltrials.gov was transformed into a mandatory registry that I created along with Representative Waxman in the 2007 FDA amendments.
Do you agree that any clinical trial regardless of where it takes place should be subject to the same transparency requirements if the trial is used as part of the company's approval application to the FDA?
So if another researcher decided to pursue clinical trials of this same drug, they would have no idea about the dangers identified from the previous trial and would put more people at risk of the same adverse health effects that had…





